Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

Recent advances in cancer therapy encounter a bottleneck. Relapsing/recurrent disease
almost always developed eventually with resistance to the initially effective drugs. Tumor …

Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …

Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …

CircRNAs are a class of competitive, endogenous, non-coding RNAs with closed-loop
structures. High-throughput sequencing indicates that circRNAs are ubiquitously expressed …

Chronic obstructive pulmonary disease (COPD) and lung cancer are frequently caused by
tobacco smoking. However, these diseases present opposite phenotypes involving redox …

The research and treatment of non-small cell lung cancer (NSCLC) have achieved some
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …

Background Two main categories of epidermal growth factor receptor (EGFR) mutations in
non–small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon …